Date：23 July (Friday)
Time: 09:00 – 10:30 (GMT+8)
Tadamitsu Kishimoto, who was born in Osaka in 1939, was President of Osaka University from 1997 to 2003 and a Member, Council for Science and Technology Policy, Cabinet office from 2004 to 2006. He is now Professor, Graduate School of Frontier Biosciences, Osaka University. He was Dean, Professor and Chairman of Department of Medicine at Osaka University Medical School from which he graduated in 1964. He is currently Japan's leading scientist in the field of life science, specifically in immunology and has made fundamental contributions to the understanding of cytokine functions through series of his studies on IL-6, its receptor system, and transcription factors. He has developed anti-IL6 receptor therapy for several immune disorders including Castleman's disease, rheumatoid arthritis and juvenile idiopathic arthritis.
He has received numerous awards, including the Imperial Prize of the Japan Academy in 1992, the Sandoz Prize for Immunology from the International Union of Immunological Society in 1992and the Avery-Landsteiner Prize from the German Immunology Society in 1996. In 1998, he was awarded the Order of Culture from Emperor. He was awarded Robert Koch Gold Medal in 2003,Honorary Life Time Achievement Awards from International Cytokine Society in 2006 and the Crafoord Award from the Royal Swedish Academy of Sciences in 2009. He has been elected a Foreign Associate of the US National Academy of Sciences in 1991, a member of the Japan Academy in 1995 and a member of German Academy of Sciences Leopoldina in 2005. He served as a president of the International Immunopharmacology Society, International Cytokine Society and the Japanese Immunology Society. He is an honorary member in American Association of Immunologists and American Society of Hematology. In 2020, He received the prestigious Tang Prize in Biopharmaceutical Science.
Blockade of interleukin (IL)-6 function by an anti-IL-6R receptor (IL-6R) antibody（tocilizumab, trade name Actemra）has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T cell therapy. Patients with serious case of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious case of COVID-19. In the first part of this presentation, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T cell therapy and COVID-19 is then discussed.
Keywords: cytokine storm, tocilizumab, cytokine release syndrome